TCR² releases early data from some PhI patients, sparking optimism from analysts
A little over a year and a half since its $100M-plus IPO, immunotherapy biotech TCR² Therapeutics $TCRR released the first data from Phase I/II trials for its lead T cell therapy today, with some analysts expressing optimism from the results.
Though the sample size is small, the data from five patients in the Phase I portion showed that none of the five individuals experienced neurotoxicity or on-target, off-tumor toxicities, a primary goal in the trial. Cytokine release syndrome manifested in three of the patients, with one dying a little over a month after treatment due to an unrelated fungal sepsis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.